Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + Chemo in Oligometastatic NSCLC
NCT05055583Phase 2Unknown
- Sponsor
- Tangdu Hospital
- Start
- Aug 2021
- Primary completion
- Aug 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in non-small cell lung cancer (NSCLC), sponsored by Tangdu Hospital. Status: unknown.
02
Drugs
toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05055583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05055583.